Skip to content
  • About
    • What we do
    • Our history
    • Our team
    • Our committees
    • Our partners
    • About genomics
  • Services
    • What we offer
    • Research we’re supporting
  • Tools & resources
    • Search all tools & resources
    • Research ethics & governance
    • Consent & patient support materials
    • Evaluating genomic research & translation
    • Data governance
    • Access our datasets
    • Data capture & standardisation
    • Data analysis & interpretation
    • Workforce education
    • Our publications
    • Our submissions
  • Our project areas
    • Our project areas
    • Genomic implementation projects 2022
    • Genomic information management
    • Clinical genomic practice
    • Genomic literacy, workforce & training
    • Indigenous genomic priorities
    • Genomic diagnostics
    • Evaluating genomic research & translation
    • Australian health system policy & practice
    • Involvement & engagement
  • News & events
    • News
    • Events
    • Personal stories
    • Search news & events
  • Connect with us
Laughing child leaning back on woman's knee

An international whole genome study to definitively map heritable risk in sarcomas

Home Research projects using our data An international whole genome study to…

Primary organisation: Garvan Institute of Medical Research (Garvan)

Principal Investigator: Professor David Thomas

Flagship requested: Acute care, Brain malformations, Epileptic encephalopathy, Genetic immunology, Leukodystrophies, Mitochondrial disorders

Co-applicants: Dr Swetansu Pattnaik (Garvan), Piyush Mundra (Garvan), Dr Mandy Ballinger (Garvan)

Approval date: September 2021 

Applicant’s project summary:

Sarcoma is a rare and complex cancer with poor prognosis and survival. While existing genetic studies in cancer have focused on common cancer types such as breast cancer, we have endeavoured to uncover the underlying genetics of sarcoma by establishing the International Sarcoma Kindred Study (ISKS) consortium. Under ISKS, we have curated a cohort of more than 3,400 sarcoma families across 23 centres in 7 countries. The goal is to better inform standard clinical care of sarcoma. We have performed whole genome sequencing (WGS) on 1,644 ISKS cases, 3,611 healthy controls and have developed a novel methodology to determine key genetic pathways implicated in sarcoma. Our analysis has revealed novel genetic signatures which will be validated in an independent study with a sarcoma cohort of 800+ cases already acquired. We now require non-cancer control WGS datasets. With independent validation of the results, we aim to expedite their clinical use.


More projects

Re-analysis of genomic data from Epileptic Encephalopathy Flagship

Genomic diagnosis and gene discovery in rare disease via analysis of existing samples and datasets

Australian Genomics and RCPA Quality Assurance Program: developing an interpretive module for genomic testing for Childhood Syndromes and ID (Medicare item: 73358)

Connect with us

(03) 9936 6345
info@australiangenomics.org.au
50 Flemington Road, Parkville
Victoria 3052 Australia

In the spirit of reconciliation Australian Genomics acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.

To stay informed about our work, sign up to our newsletter

Subscribe

Quicklinks

  • Home
  • What we do
  • What we offer
  • Tools & resources
  • Our publications
  • Our project areas
  • Research we’re supporting
  • Our team

Privacy

  • We follow the Australian Privacy Principles
  • General privacy policy
  • Website privacy policies
  • Terms & conditions

Website by Blueboat.